On-chip III-V monolithic integration of heralded single photon sources and beamsplitters

We demonstrate a monolithic III-V photonic circuit combining a heralded single photon source with a beamsplitter, at room temperature and telecom wavelength. Pulsed parametric down-conversion in an AlGaAs waveguide generates counterpropagating photons, one of which is used to herald the injection of its twin into the beamsplitter. We use this configuration to implement an integrated Hanbury-Brown and Twiss experiment, yielding a heralded second-order correlation $g^{(2)}_{\rm her}(0)=0.10 \pm 0.02$ that confirms single-photon operation. The demonstrated generation and manipulation of quantum states on a single III-V semiconductor chip opens promising avenues towards real-world applications in quantum information

Hypocalcémie post-thyroïdectomie

Introduction : L’hypocalcémie est la complication la plus préoccupante de la thyroïdectomie totale. Elle impose un traitement substitutif et un suivi à vie. Objectifs : Le but de cette étude est d’évaluer l’incidence de l’hypocalcémie après chirurgie et d’étudier sa corrélation avec les caractéristiques cliniques, biologiques et le type de chirurgie pratiqué. Matériels et méthodes : Etude rétrospective portant sur 488 cas de thyroïdectomies, opérées entre 1992 et 1996. L’hypocalcémie est définie par une calcémie inférieure à 80 mg/l «2 mmol/l ». Les patients, toujours dépendants d’un traitement substitutif un an après la chirurgie, ont été considérés comme ayant une hypocalcémie définitive. Résultats : Dans notre étude, 368 patients ont eu une thyroïdectomie totale et 120 ont eu une thyroïdectomie subtotale. Le goitre multinodulaire était la pathologie la plus fréquente, noté dans 359 cas, suivie des cancers thyroïdiens noté dans 83 cas. L’hypocalcémie postopératoire a été retrouvée chez 54 patients (11,06%) dont 25 étaient asymptomatique. Cette hypocalcémie s’est révélée définitive chez 14 d’entre eux (2,8%). Nous n’avons pas trouvé de corrélation statistiquement significative entre l’hypoparathyroïdie définitive et les caractéristiques cliniques biologiques et le type de chirurgie.Conclusion : Dans la plupart des cas, l’hypocalcémie est liée à un hypoparathyroïdisme transitoire, secondaire au traumatisme ou à la dévascularisation des parathyroïdes. L’hypoparathyroïdie définitive est rare, elle est toujours secondaire à une lésion irréversible des parathyroïdes. Les caractéristiques cliniques initiales des patients et les examens biologiques précoces ne permettent pas de prédire l’évolution.Mots-clés : Thyroïde, chirurgie, hypocalcémie, parathyroïde

Recidive tardive d'un sarcome a cellule claire

Introduction : The clear cell sarcoma (melanoma of soft tissue) is a rare tumor of young adults. Hi occur most commonly in the extremities. We report the case of a man of 70 years, with previous history of a malignant melanoma of the cervical trachea treated by radiotherapy, who present 18 years after Tracheo-esophageal tumor. The tumor was totally removed.Final pathologic diagnosis is a recurrence of his sarcoma cell clear. Three years later, the patient has no signs of recurrence. The aim of this work is to study the clinical features, the prognosis of these cancers and the modality of her treatments.Keywords: the clear cell sarcoma, melanoma of soft tissue, radiotherapy, surgery

Intérêt de la technique de Koyanagi dans le traitement de l’hypospadias posterieurchez l’enfant

No Abstrac

Recurrent cardiac events in patients with idiopathic ventricular fibrillation, excluding patients with the Brugada syndrome

BACKGROUND: The recurrence of cardiac events in patients with idiopathic ventricular fibrillation (VF) excluding patients with the Brugada syndrome is unclear since this entity remains present in previous studies. METHODS: Since 1992, 18 patients (72% male) with idiopathic VF out of 455 ICD implants were treated with an implantable cardioverter defibrillator (ICD). The mean age at first ICD implantation was 42 ± 14 years. Brugada syndrome, as well as other primary electrical diseases (e.g. long QT), were systematically excluded in all patients by the absence of the typical electrocardiogram (ST elevation in the right precordial leads) at rest and/or after pharmacological tests (ajmaline, flecainide, or procainamide). Recurrence of cardiac events was prospectively assessed. RESULTS: During a mean follow-up period of 41 ± 27 months, VF recurrence with appropriate shock occurred in 7 patients (39%) covering a total of 27 shocks. The median time to first appropriate shock was 12 ± 9 months. There were no deaths. In the electrophysiological study, 39% of patients were inducible, but inducibility failed to predict subsequent arrhythmic events. Forty-four percent of patients suffered 21 inappropriate shocks, which were caused by sinus tachycardia, atrial arrhythmias or lead malfunction. CONCLUSION: Idiopathic ventricular fibrillation patients have a high recurrence rate of potentially fatal ventricular arrhythmias, excluding patients with the Brugada syndrome or other known causes. ICD prevents sudden cardiac death but inappropriate shocks remained a major issue in this young and active population

Comparative methods for PET image segmentation in pharyngolaryngeal squamous cell carcinoma

Several methods have been proposed for the segmentation of ¹⁸F-FDG uptake in PET. In this study, we assessed the performance of four categories of ¹⁸F-FDG PET image segmentation techniques in pharyngolaryngeal squamous cell carcinoma using clinical studies where the surgical specimen served as the benchmark

Rationale, design and population baseline characteristics of the PERFORM Vascular Project: an ancillary study of the Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic attack (PERFORM) trial

<p><b>Purpose</b></p> <p>PERFORM is exploring the efficacy of terutroban versus aspirin for secondary prevention in patients with a history of ischemic stroke or transient ischemic attacks (TIAs). The PERFORM Vascular Project will evaluate the effect of terutroban on progression of atherosclerosis, as assessed by change in carotid intima-media thickness (CIMT) in a subgroup of patients.</p> <p><b>Methods and results</b></p> <p>The Vascular Project includes structural (CIMT, carotid plaques) and functional (carotid stiffness) vascular studies in all patients showing at least one carotid plaque at entry. Expected mean follow-up is 36 months. Primary endpoint is rate of change of CIMT. Secondary endpoints include emergent plaques and assessment of carotid stiffness. 1,100 patients are required for 90% statistical power to detect treatment-related CIMT difference of 0.025 mm. The first patient was randomized in April 2006.</p> <p><b>Conclusions</b></p> <p>The PERFORM Vascular Project will investigate terutroban’s effect on vascular structure and function in patients with a history of ischemic stroke or TIAs.</p&gt